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A B S T R A C T
Background
It is believed that ivermectin (a microfilaricide) could prevent blindness due to onchocerciasis. However, when given to everyone in
communities where onchocerciasis is common, the effects of ivermectin on lesions affecting the eye are uncertain and data on whether
the drug prevents visual loss are unclear.
Objectives
The aim of this review was to assess the effectiveness of ivermectin in preventing visual impairment and visual field loss in onchocercal
eye disease. The secondary aim was to assess the effects of ivermectin on lesions affecting the eye in onchocerciasis.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2012, Issue 3),
MEDLINE (January 1950 to April 2012), EMBASE (January 1980 to April 2012), the metaRegister of Controlled Trials (mRCT) (
www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last
searched the electronic databases on 2 April 2012.
Selection criteria
We included randomised controlled trials with at least one year of follow-up comparing ivermectin with placebo or no treatment.
Participants in the trials were people normally resident in endemic onchocercal communities with or without one or more characteristic
signs of ocular onchocerciasis.
Data collection and analysis
Two review authors independently extracted data and assessed trial quality. We contacted study authors for additional information. As
trials varied in design and setting, we were unable to perform a meta-analysis.
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Main results
The review included four trials: two small studies (n = 398) in which people with onchocercal infection were given one dose of
ivermectin or placebo and followed up for one year; and two larger community-based studies (n = 4941) whereby all individuals in
selected communities were treated every six or 12 months with ivermectin or placebo, whether or not they were infected, and followed
for two to three years. The studies provide evidence that treating people who have onchocerciasis with ivermectin reduces the number of
microfilariae in their skin and eye(s) and reduces the number of punctate opacities. There was weaker evidence that ivermectin reduced
the risk of chorioretinitis. The studies were too small and of too short a duration to provide evidence for an effect on sclerosing keratitis,
iridocyclitis, optic nerve disease or visual loss. One community-based study in communities mesoendemic for the savannah strain of
O.volvulus provided evidence that annual mass treatment with ivermectin reduces the risk of new cases of optic nerve disease and visual
field loss. The other community-based study of mass biannual treatment of ivermectin in communities affected by the forest strain of
O.volvulus demonstrated reductions in microfilarial load, punctate keratitis and iridocyclitis but not sclerosing keratitis, chorioretinitis,
optic atrophy or visual impairment. The study was underpowered to estimate the effect of ivermectin on visual impairment and other
less frequent clinical signs. The studies included in this review reported some adverse effects, in particular an increased risk of postural
hypotension in people treated with ivermectin.
Authors’ conclusions
The lack of evidence for prevention of visual impairment and blindness should not be interpreted to mean that ivermectin is not
effective, however, clearly this is a key question that remains unanswered. The main evidence for a protective effect of mass treatment
with ivermectin on visual field loss and optic nerve disease comes from communities mesoendemic for the savannah strain ofO.volvulus.
Whether these findings can be applied to communities with different endemicity and affected by the forest strain is unclear. Serious
adverse effects were rarely reported. None of the studies, however, were conducted in areas where people are infected with Loa loa
(loiasis).
P L A I N L A N G U A G E S U M M A R Y
Ivermectin for river blindness (onchocerciasis)
Onchocerciasis is caused by tiny worms and is transmitted from person to person by a small biting fly. The fly breeds in fast flowing
rivers and streams mainly in West Africa. The disease causes severe itching and thickening of the skin and damages structures at the
front and back of the eye. It also affects the nerve that connects the eye with the brain.
Four studies based in west Africa were included in the review; two small studies in Ghana and Liberia and two larger community-
based ones in Nigeria and Sierra-Leone. In the smaller studies, people with onchocercal infection were given one dose of ivermectin or
placebo and followed up for one year. In the larger studies all individuals in selected communities were treated every six or 12 months
with ivermectin or placebo, whether or not they were infected, and followed for two to three years. This review found that ivermectin
can prevent damage to the front of the eye but its effectiveness in preventing blindness remains uncertain.
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B A C K G R O U N D
Description of the condition
Onchocerciasis is an insect-borne disease caused by the filaria ne-
matode (Onchocerca volvulus). It is transmitted from person to per-
son by black-flies (Simulium species). Onchocerciasis is also called
river blindness because the black-fly vector breeds in fast-flowing
rivers and transmission is generally limited to people who live or
work near such rivers.
The infective worms enter the human body through the black-
fly bite and develop into mature adult worms (macrofilariae). The
adult worms mate and the adult female produces millions of baby
worms (microfilariae) which migrate throughout the skin. The ac-
tual route of entry of microfilariae into the eye is not known but
proposed routes include the sheaths of the posterior ciliary arter-
ies and nerves (arteries and nerves supplying the eye), the blood
circulation, the cerebrospinal fluid and along the orbital septum
and the cheek ligaments. Microfilariae may be seen in the cornea
(the transparent outer wall of the eye) or the anterior chamber
(the space between the cornea and the iris) by the slit lamp (an
optical microscope used for examining the eye). While alive, the
microfilariae cause little or no inflammation or immune response.
Onchocercal eye disease generally develops after a long exposure
to onchocercal infection, although eye lesions may occur rapidly
when the intensity of infection is high. Generally, eye lesions tend
to appear in individuals between the age of 30 and 45 years and
are usually more commonly seen in males who work outdoors.
The main pathological changes seen in the back of the eye appear
to be related to the local invasion and death of the microfilar-
iae within the retinal tissue (Burnham 1998). It is believed that
the dead microfilariae precipitate a severe inflammatory reaction
which leads to the characteristic lesions affecting the back of the eye
associated with ocular morbidity and blindness (Winthrop 2011).
Additional research has identifiedWolbachia, a bacteria which lives
symbiotically within themature adults worms (Saint Andre 2002).
The presence of theWolbachia or microfilariae may be responsible
for the inflammatory immune response in front of the eye which is
associated with punctate keratitis (inflammatory changes seen in
the cornea that appear as fluffy white opacities); sclerosing keratitis
(severe inflammatory changes seen in the cornea associated with
corneal scarring); and iridocyclitis (inflammatory changes seen in
the iris) (Hise 2007; Saint Andre 2002).
The pathogenesis of the lesions affecting the back of the eye: chori-
oretinitis (inflammation of the choroid and the retina); and optic
neuritis (inflammation of the optic nerve) with subsequent optic
atrophy (loss of nerve fibres in the optic nerve) is less clear and
somewhat controversial. An autoimmune pathogenesis has been
proposed based on the observation of the structural similarity be-
tween an onchocerca volvulus antigen (Ov39) and a human retinal
antigen (hr44) (Cooper 1996). This similarity may initiate the
development of an autoimmune disease that has the potential to
progress even in the absence of the organism. In other words, the
chorioretinal pathology is initiated by the presence of local micro-
filariae, whereas the extension of the lesions does not require their
presence (Cooper 1997). This would explain why the decrease in
ocular microfilarial loads following ivermectin treatment reported
in some trials does not interrupt the pathological process in the
retina which probably was initiated early in life (i.e. before the age
of 15 years) (Chippaux 1999). This raises the question of whether
treatment with ivermectin can be expected to prevent progres-
sive posterior segment disease or indeed long-term blindness from
this cause. The main pathways to blindness due to onchocerciasis
are sclerosing keratitis, chorioretinitis and optic nerve disease, al-
though blindness can result from lesions that affect different parts
of the eye i.e. iridocyclitis leading to secondary cataract (opacity of
the lens within the eye) or secondary glaucoma (increase in pres-
sure within the eye).
Onchocerciasis is endemic in 34 countries; 26 in the African re-
gion, six in the region of the Americas and two in the Eastern
Mediterranean (Johnson 1998). As a public health problem the
disease is most closely associated with Africa, where it constitutes
a serious obstacle to socio-economic development. Recent esti-
mates indicate that about 18 million people globally are infected
of whom 99% are in Africa (WHO 2000). A further 120 million
people world-wide are at risk of developing the disease, 96% of
whom are in Africa (WHO 2000).
Onchocerciasis causes severe skin disease but the main public
health importance of the disease is blindness. Of the 18 million
people infected with the disease an estimated 270,000 are blind
and 500,000 severely visually disabled (Rolland 1974). The overall
consequences of onchocerciasis can only be fully appreciated when
uni-ocular blindness, visual impairment and constriction of the
peripheral visual field are taken into consideration (Abiose 1994;
Murdoch 1997).
Description of the intervention
Ivermectin (marketed as Mectizan), a microfilaricide, has been
used for the treatment of parasites of domestic animals for many
years. In 1982 ivermectin was tested in patients with onchocercia-
sis and was found to reduce significantly themicrofilarial counts in
skin snips of infected individuals for a period of six months to one
year (Aziz 1982). It has been suggested from dose-finding trials
that 150 micrograms/kg body weight represents an optimal dose
of ivermectin (White 1987). The exclusion criteria for ivermectin
use include children less than five years; pregnant women; women
breastfeeding within one month of giving birth and individuals
with disorders of the central nervous system (such as epilepsy).
Clinical trials and subsequent field experience have shown that
ivermectin is a rapidly effective, well-tolerated, single dose, mi-
crofilaricide which causes little or no Mazzotti reaction (severe in-
flammatory response) and is suitable for use in mass campaigns
(Johnson 1998). Commonly reported adverse effects after iver-
mectin use are skin reactions including itching; musculoskeletal
5Ivermectin for onchocercal eye disease (river blindness) (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
pains; fever; swelling of the face, joints and limbs; headaches and
dizziness; lymphadenopathy; eye reactions and nodule pain.These
are usually mild and self-limiting. Some individuals may develop
a severe symptomatic postural hypotension (a sudden fall in blood
pressure) which may require emergency facilities for resuscitation.
Concerns have been expressed recently over the potential for iver-
mectin to cause unconsciousness in treated individuals who have
concomitant Loa loa infection (another kind of filarial worm in-
festation), with very high microfilaraemia. Gardon 1997 reported
two cases of probable Loa encephalopathy after mass treatment
of about 17,877 persons with ivermectin in the Lekie area of
Cameroon, where onchocerciasis and loiasis are both endemic.
Consequently it has been proposed that, before launching mass
ivermectin distribution programs, communities in which the in-
tensity of concomitant Loa loa microfilaraemia are highly in need
of being identified and monitoring strategies instituted before
treatment begins (Boussinesq 1998).
Apart from its use in controlling onchocerciasis, it has been re-
ported that ivermectin has a secondary effect of reducing intestinal
helminths in humans. Whitworth 1991b showed that ivermectin
had a significant effect on Ascaris (round worm) infection, reduc-
ing prevalence and intensity for at least three months. In a qualita-
tive study in north-east Nigeria on community-perceived benefits
of ivermectin treatment, worm expulsion was the most frequently
stated benefit (Akogun 2000). Other perceived benefits were an
increase in vitality, sexual drive and performance.
How the intervention might work
Although the exact pharmacological action of ivermectin is not
well known, it is believed to exert its anti-parasitic action on mi-
crofilariae either by acting directly as a Gaba-amino-butyric-acid
(GABA) agonist or by causing an increase in tonic GABA release.
It may therefore interfere with neural transmission causing paral-
ysis of parasites (Aziz 1982). Apart from its microfilaricidal ef-
fects, ivermectin has also been observed to inhibit the release of
microfilariae from the adult worm’s uterus. The end result of these
actions is a reduction in microfilarial loads in the body and eyes,
prevention of progression of onchocercal lesions in the eye and
skin and possibly prevention of blindness in the long term.
The control of onchocerciasis as a public health problem was
achieved with the introduction of treatment with ivermectin an-
nually or every six-months in endemic communities. However,
there is some debate regarding the potential role of annual mass
treatment with ivermectin in reducing transmission in endemic
communities in order to achieve elimination to the extent at which
treatment may be stopped (Abiose 2000; Richards 2000). It has
been shown that distribution of ivermectin to 60% of the popula-
tion results in a 70% to 75% post-treatment reduction in infected
flies (Remme 1990). Similarly,mass treatment with ivermectin has
been shown to be associated with a 94% reduction in the number
of flies with developing infective larvae (Trpis 1990). Repeated an-
nual treatment with ivermectin in Liberia was shown to reduce the
incidence of new infections in untreated children by about 40%
in the second year (Taylor 1990). Based on longitudinal research
treatment over 15 to 17 years can interrupt transmission and re-
duce the expected number of new infections below levels postu-
lated to achieve elimination (Diawara 2009; Tekle 2012). Even
after treatment was stopped no new infections or transmission was
detected after two years of follow-up (Diawara 2009). It is now
believed that new infections and interruption of transmission can
be achieved with treatment alone in endemic areas (Diawara 2009;
Tekle 2012).
Whitworth 1992Remme 1990
Why it is important to do this review
The control of onchocerciasis has been based at various times
on large-scale nodulectomy, vector control or large-scale chemo-
therapy. The chemotherapeutic agents used prior to 1987 were
suramin and diethylcarbamazine. While suramin was a good
macrofilaricide (efficacious in killing the adult worms), it requires
intravenous injection and was found to be toxic to the kidneys.
Diethylcarbamazine, a microfilaricide (efficacious in killing the
baby worms), was associated with the development of the Maz-
zotti reaction, in which massive destruction and death of the baby
worms stimulated a severe inflammatory response. This was shown
to precipitate and accelerate the progression of optic nerve disease
in individuals with a heavy onchocercal infection (Bird 1980).
TheWorldHealthOrganization (WHO) has defined a new global
strategy for controlling onchocerciasis that is based on yearly ad-
ministration of single doses of ivermectin to affected populations
(WHO 2000). Ivermectin is currently employed by the African
Programme for Onchocerciasis Control (APOC) and the On-
chocerciasis Elimination Programme for the Americas (OEPA) for
mass treatment in hyper andmesoendemic communities. In 1987,
Merck & Co., Inc. pledged to provide, at no cost, all the drugs
necessary for as long as needed to overcome onchocerciasis as a
public health problem. Between 1987 and the end of 1996, more
than 65 million doses of ivermectin had been donated for distri-
bution (WHO 2000).
Blindness remains the single most important public health prob-
lemposed by onchocerciasis. Although ivermectin has been shown
to be an excellent microfilaricide, it is unclear how this translates
to real benefits in terms of blindness prevention for those who
suffer the disease. The microfilaricidal activity of ivermectin, no
matter how great, is of only academic interest if a villager at risk of
blindness from onchocerciasis cannot be told in clear terms how
taking the drug reduces that risk. So far, evaluation of the effec-
tiveness of ivermectin in preventing blindness has been based on
surrogate measures such as the reduction of skin and ocular micro-
filarial loads, as well as possible improvement in anterior segment
lesions (lesions affecting the front of the eye) such as punctate
keratitis, sclerosing keratitis or iridocyclitis or some of the poste-
6Ivermectin for onchocercal eye disease (river blindness) (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
rior segment lesions (lesions affecting the back of the eye) such as
chorioretinitis or optic nerve disease. However, there are conflict-
ing reports concerning the effects of ivermectin on these lesions as
well as uncertainties about its effectiveness in preventing progres-
sive visual loss especially from lesions affecting the back of the eye.
This review, therefore, aimed to summarise systematically all the
evidence from randomised controlled trials (RCTs) relating to the
effectiveness of ivermectin in preventing progressive visual loss as
well as its effects on onchocercal eye lesions in order to provide
current best evidence on which to base decisions for practice and
further research.
O B J E C T I V E S
The primary objective of this review was to assess the effectiveness
of ivermectin on the prevention of visual loss in onchocercal ocular
disease. A secondary objectivewas to assess the effects of ivermectin
on onchocercal ocular lesions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
This review included RCTs. The unit of randomisation was either
individuals or endemic onchocercal communities (cluster RCTs).
Included trials were required to have at least a one-year follow-up.
Types of participants
Participants were people who were normally resident in a com-
munity that was endemic for onchocerciasis, with or without a
positive skin snip for microfilariae or to have characteristic ocular
signs of onchocerciasis. Participants could also be grouped as com-
munities where the unit of randomisation was at the community
level.
Types of interventions
We included RCTs comparing ivermectin treatment with placebo
or no intervention. Treatment was defined according to the rec-
ommended dose of 150 micrograms ivermectin tablet per kg body
weight, taken orally as a single dose semi-annually or annually.
Types of outcome measures
Primary outcomes
The primary outcomes for this review were as follows.
1. Visual acuity: the proportion of participants with new visual
acuity loss (unilateral or bilateral) during the follow-up period.
2. Visual fields: the proportion of participants with new visual field
deterioration (unilateral or bilateral) during the follow-up period.
Case definitions for primary outcome measures.
• New visual acuity loss: any case of visual impairment or
blindness.
• New visual impairment: deterioration of visual acuity with
best correction in either eye to less than 6/18 during the study
period.
• New blindness: deterioration of visual acuity with best
correction in either eye to less than 3/60 during the study period.
• Visual field deterioration: as defined by trial authors.
Secondary outcomes
The secondary outcomes for this review were as follows.
3. Parasitological - mean microfilariae count or proportion of par-
ticipants with a microfilariae count more than one in:
a. cornea;
b. anterior chamber;
c. skin.
4. Clinical - new cases, progression or proportion of participants
with:
a. punctate keratitis;
b. sclerosing keratitis;
c. iridocyclitis;
d. chorioretinitis;
e. optic nerve disease.
5. Adverse outcomes as reported in trials.
Secondary outcomes were as measured by the trial investigators
and were considered according to the unit of randomisation in
each study - either at the individual or community level.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) 2012, Issue 3, part of The Cochrane Li-
brary. www.thecochranelibrary.com (accessed 2 April 2012),
MEDLINE (January 1950 to April 2012), EMBASE (Jan-
uary 1980 to April 2012), the metaRegister of Controlled
Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (
www.clinicaltrials.gov) and theWHOInternational Clinical Trials
Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We
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did not use any date or language restrictions in the electronic
searches for trials. We last searched the electronic databases on 2
April 2012.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1), MEDLINE (Appendix 2), EMBASE (Appendix
3), mRCT (Appendix 4), ClinicalTrials.gov (Appendix 5) and the
ICTRP (Appendix 6).
Searching other resources
We searched the reference lists of identified trials to find additional
trials. We used the Science Citation Index to find studies that
had cited the identified trials. We contacted the investigators of
the identified trials, Merck & Co., Inc. and practitioners who are
active in the field (A Foster, UK; D Molyneux, UK; I Murdoch,
UK) to identify additional published and unpublished studies.
Attempts to contact Hans Remme of the WHO Onchocerciasis
Control Project were unsuccessful.
Data collection and analysis
Selection of studies
Two review authors independently reviewed the titles and abstracts
resulting from the searches. We obtained full copies of any report
referring to possibly or definitely relevant trials. All full copies were
assessed according to the Criteria for considering studies for this
review.Only trialsmeeting these criteria were assessed formethod-
ological quality. Disagreements were resolved by discussion.
Data extraction and management
Two review authors extracted data using a form developed by the
Cochrane Eyes and Vision Group and entered data into RevMan
(Review Manager 2011). We resolved discrepancies by discussion.
We combineddata on the proportionof participantswith early and
advanced stages of the following lesions - keratitis, iridocyclitis,
chorioretinitis and optic nerve disease. i.e. data on early and late
keratitis were combined to give data on keratitis as an outcome.We
combined data for the number of participants with a microfilariae
count between one and four and those with a microfilariae count
above four into the proportion of participants with a microfilariae
count of more than one.
Assessment of risk of bias in included studies
For the first version of this review, we assessed trial quality ac-
cording to methods set out in Section 6 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2005). Four
parameters were considered: allocation concealment; masking of
participants and providers; masking of outcome assessment; and
completeness of follow-up. Each parameter for trial quality was
graded: A (adequate); B (unclear); C (inadequate). The a priori
criterion for exclusion was that trials scoring C on allocation con-
cealment were excluded. Two review authors independently as-
sessed trial quality and disagreement was resolved by discussion.
Review authors were not masked to the report authors and trial
details during the assessment.
For the update in 2009 The Cochrane Collaboration’s recom-
mended tool for assessing risk of bias was used. This is a domain-
based evaluation of allocation, blinding, incomplete outcome data
and selective reporting. The ’Risk of bias’ tables were completed
by one review author (JE) and checked by another author (HE).
For the 2012 update, the review authors’ judgements within the
’Risk of bias’ tabes were labelled as: high; low; or unclear risk of
bias as described in Higgins 2011.
Measures of treatment effect
We calculated risk ratios for outcome measures reported as di-
chotomous data. We did not calculate summary measures for out-
come measures reported as continuous data as neither standard
deviations nor confidence intervals were reported.
Unit of analysis issues
We had anticipated that there would be cluster randomised trials
available for this review, however, none were identified. All trials
reported outcomes per person, not per eye.
Dealing with missing data
Ourmain analyses assume thatmissing data aremissing at random.
However, to see how reasonable this assumption might be we also
performed sensitivity analyses with different assumptions about
the missing data using methods as set out by White et al (White
2008). The “informative missingness odds ratio” (IMOR) refers
to the ratio of the odds of the outcome among participants for
whom data were missing and the odds of the outcome among
participants who were observed. These IMORs can be assumed
to be equal or different in the two trial arms. We performed four
sensitivity analyses for selected outcomes. Firstly, we assumed the
IMOR was 2 in treatment and control groups i.e. that people who
were not seen were twice as likely to have the outcome. Secondly,
we assumed that the IMORwas 1/2 in both treatment and control
groups i.e. that people who were not seen were half as likely to
have the outcome. For the third and fourth sensitivity analyses, we
assumed that the IMOR was opposite in treatment and control
groups - i.e. 2 or 1/2.
We carried out all analyses using the metamiss command in Stata
(version10.1, StataCorpLP, 4905LakewayDrive,College Station,
TX 77845 USA).
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Assessment of heterogeneity
We assessed heterogeneity by examining the forest plots and I2
values.
Assessment of reporting biases
Weplanned to investigate publication bias by carrying out a scatter
plot of the effect estimates from the individual studies against their
standard error. An asymmetric graph may indicate that smaller
studies that are not statistically significant have not beenpublished,
although it also may indicate that the effects of treatment are
different in small studies. Currently not enough trials are included
in the analyses to assess publication bias.
We investigated selective outcome reporting by carrying out an
“outcome matrix” and classifying missing outcomes according to
the following classification (adapted from a list provided by Paula
Williamson at aCochrane trainingworkshop on selective outcome
reporting bias, Edinburgh March 2009).
A: States outcome analysed but only reported the P value > 0.05
i.e. NS
B: States outcome analysed but only reported that P value < 0.05
C:Clear that outcome was analysed but insufficient data presented
to be included in meta-analysis or full tabulation
D: Clear that outcome was analysed but no results reported
E: Clear that outcome was measured (for example, includes struc-
turally related outcomes) but not necessarily analysed
F: States that outcome was not measured
G: Not mentioned but clinical judgement says likely to have been
measured
H: Not mentioned but clinical judgement says unlikely to have
been measured
I: Other give details
Data synthesis
Due to the variable methods used in trials for collecting and pre-
senting outcome data, we considered pooling of results inappro-
priate.
Subgroup analysis and investigation of heterogeneity
Analyses of subgroups were not specified a priori and therefore we
did not perform any in this review.
Sensitivity analysis
See ’Dealing with missing data’ section above.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The original electronic searches in February 2000 generated 347
citations and abstracts. These were screened and 92 full text articles
were retrieved for further assessment. Five RCTs, reported in 10
articles,met the criteria for inclusion.CommunicationwithMerck
& Co., Inc, the manufacturers of Mectizan, and with experts in
the field did not yield information on any further trials.
The following table summarises the updates:
Date Number of new citations Number of new studies for inclusion
February 2000 347 5 (subsequently revised to 4 as one report was of a subset of patients included in
another trial)
December 2001 13 None
May 2005 173 None
December 2008 126 None
August 2009 33 None
April 2012 135 None
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Included studies
Table 1 summarises the characteristics of the included studies.
Setting and participants
All four studies took place in west Africa: Liberia (Taylor 1988),
northern Nigeria (Abiose 1993), northern Ghana (Dadzie 1989)
and southern Sierra-Leone (Whitworth 1991a). All the studies
recruited participants normally resident in endemic onchocercal
communities.
Interventions
In all trials ivermectin was compared with placebo. The usual dose
was 150 µg/kg body weight, however, Dadzie 1989 and Taylor
1988 had three treatment groups of 100,150 and 200 µg/kg. As
the results of these groups were similar they have been pooled for
the purposes of this review. Ivermectin was given as a single dose
in Dadzie 1989 and Taylor 1988. In the community-based studies
four annual (Abiose 1993) or biannual (Whitworth 1991a) doses
were given.
Outcome measures
Assessment of outcome measures was by ocular or systemic ex-
amination. This included skin snip tests and visual field examina-
tion in some cases. The assessments were undertaken by specialist
doctors or specially trained eye nurses. Outcome measures were
assessed and reported differently in the studies. For example, in
Abiose 1993 visual field was assessed using the Friedmann Mark
1 Visual Field Analyser and visual field deterioration was defined
as an absolute loss of at least 19 illuminated spots. In Taylor 1988
visual field was assessed using the clear dome perimeter with a
2 mm fibre-optic target, and visual field classified as either full,
showing peripheral loss, loss to 20° of fixation, loss to 10° or loss
to 5°. We have presented a descriptive report of the analyses of
data from each of the four included trials.
For more detailed information on individual trials see ’
Characteristics of included studies’.
Excluded studies
See ’Characteristics of excluded studies’.
Risk of bias in included studies
Figure 1 and Figure 2 summarise the assessment of the risk of bias
in the included studies.
Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
Allocation
Abiose 1993 was the only trial that reported adequate methods
of sequence generation and allocation concealment. Dadzie 1989
and Taylor 1988 reported adequate methods of allocation conceal-
ment. For Whitworth 1991a, methods for sequence generation
and allocation concealment were not reported.
Blinding
All trials were placebo-controlled so we have assumed that partici-
pants and outcome assessors were adequately masked to treatment
group.
Incomplete outcome data
Table 2 shows the follow-up data for the included trials. Follow-up
rates ranged from 73% (Taylor 1988) to 89% (Whitworth 1991a).
However, the latter study only reported information from people
who had received all four biannual doses of ivermectin or placebo.
Losses to follow-up in the main trial were not given.
In Abiose 1993 communities endemic for onchocerciasis were
treated, that is everyone aged five years and above received iver-
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mectin or placebo, however, children under the age of 15 years
were not examined at follow-up. Although this means that not ev-
eryone treated was examined, it is hard to envisage that this would
bias the resulting effect estimates as very few events would be ex-
pected in people aged five to 15 and there is no reason to suppose
that the effect of ivermectin will be different in this age group.
Selective reporting
Data were reported rather sparsely for most outcomes. Table 3
shows the outcome reporting grid. There is considerable potential
for selective outcome reporting.
Effects of interventions
See: Summary of findings for the main comparison Ivermectin
to prevent and treat onchocercal eye disease in people infected
with O.volvulus; Summary of findings 2 Ivermectin to prevent
and treat onchocercal eye disease in people living in communities
affected by O.volvulus
Primary outcome measures
1. Visual acuity (visual impairment and blindness)
All four studies collected data on visual acuity.
Abiose 1993 did not report visual acuity outcome data.
Dadzie 1989 stated that 2% of participants showed deterioration
in their visual acuity in the course of the follow-up examinations
(12 months) without giving absolute figures for each treatment
group. These differences were not statistically different between
the four treatment groups.
Taylor 1988 observed 0/152 (0%) participants in the ivermectin
groups and 1/48 (2.1%) participants in the placebo group devel-
oped visual acuity deterioration from 6/6 to 6/9 during the 12-
month follow-up period. The definition of visual acuity deterio-
ration used in the trial does not meet the definition used for this
review. It does, however, imply that no participant developed vi-
sual impairment or blindness over the course of the study.
Whitworth 1991a reported explicitly data for the incidence of
blindness and visual impairment. The definition used for blind-
ness and visual impairment was consistent with the WHO guide-
lines. In this trial, six out of 255 people who were not visually
impaired at baseline (2.4%) and who received four six-monthly
doses of ivermectin developed visual impairment compared with
5/230 (2.3%) in the placebo group after four six-monthly doses
of ivermectin or placebo (risk ratio (RR) 1.08, 95% confidence
interval (CI) 0.33 to 3.50).
2. Visual fields
Abiose 1993 reported the effect of ivermectin on visual field dete-
rioration. Of the participants who were treated with at least one
dose of ivermectin and completed a Friedmann field analysis at
one ormore of the follow-up examinations, 34/314 (10.8%) in the
ivermectin group developed visual field deterioration compared
with 58/322 (18%) in the placebo group (RR 0.60, 95% CI 0.41
to 0.89). We assessed the effects of missing data for this outcome
(Table 4). There was little evidence that this effect could be at-
tributed to the effects of missing data.
Dadzie 1989 collected data on visual field at baseline but did not
report post-treatment visual field outcomes.
Taylor 1988 reported no case of further visual field deterioration
during the period of follow-up (12 months) between the iver-
mectin and placebo groups.
Whitworth 1991a did not include visual field outcomes.
Secondary outcome measures
3. Parasitological
Abiose 1993 did not report parasitological outcomes.
Two trials (Dadzie 1989; Taylor 1988) reported parasitological
outcome measures as continuous data (shown in the following
table) but as they did not report standard deviations or confidence
intervals we could not pool the data.
Out-
come 12 months af-
ter one dose of iver-
mectin at baseline
Study Ivermectin Placebo
Geometric mean at
baseline (before treat-
ment)
Geometric mean at
12 months
Geometric mean at
baseline (before treat-
ment)
Geometric mean at
12 months
Number of microfi-
lariae per mg skin
Taylor 1988 20.0 3.4 21 13
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(Continued)
*Number of micro-
filariae in the ante-
rior chamber
Dadzie 1989 6 0.2 4 1.3
Taylor 1988 2.6 0.2 3.8 1.7
*Number of micro-
filariae in the cornea
Dadzie 1989 0.35 0 0.3 0.05
Taylor 1988 0.4 0.15 0.65 0.7
*Approximate values as they are obtained from graphical output.
Differences between ivermectin and placebo groups were reported
to be statistically significant (P < 0.05).
Whitworth 1991a reported parasitological outcomes measured as
categorical data.
Outcome after 4 doses of iver-
mectin at six-monthly intervals
(2 years follow-up)
Ivermectin n/N Placebo n/N Risk ratio (95% confidence intervals)
Proportion with anterior cham-
ber microfilarial count > 1
10/285 91/263 0.10 (0.05 to 0.19)
Proportion with corneal micro-
filarial count > 1
17/285 61/263 0.21 (0.12 to 0.37)
4. Clinical
Abiose 1993 Dadzie 1989 Taylor 1988 Whitworth 1991a
Outcome n/N in ivermectin group,
n/N in placebo group.
One or more doses (max
four) over 3 years. Mean
duration of follow-up 2.
54 years (range 1.41 to 3.
25)
Figures are ge-
ometric means at baseline
(before treatment) and 12
months after one dose of
ivermectin
n/N in ivermectin group,
n/N in placebo group at
after 4 six-monthly doses
of ivermectin i.e. 2 yrs
follow-up risk ratio (RR)
(95% confidence inter-
vals)
Punctate keratitis Not reported “At one year all ivermectin
treated groups showed
a zero level whilst the
placebo treated group was
at 50% of the level before
treatment”
Num-
ber of punctate opacities:
baseline 0.8 (ivermectin)
1.2 (placebo): 12 months
0.1 (ivermectin) and 1.0
(placebo)
One or more
punctate opacities 27/288
(ivermectin) and 75/263
(placebo) RR 0.33 (0.22
to 0.49)
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(Continued)
Sclerosing keratitis Not reported Not reported In a subsample of 39 par-
ticipants with severe oc-
ular onchocerciasis, there
was a progression of scle-
rosing keratitis in 2/9 (22.
2%) participants in the
placebo group compared
with 0/30 (0%) in the
ivermectin group (OR 0.
18, 95% CI 0.01 to 4.29)
83/293 (ivermectin) and
93/267 (placebo) RR 0.
74 (0.52 to 1.06)
Iridocyclitis Not reported 7/
116 in ivermectin group
and 0/38 placebo group
had mild iridocyclitis that
resolved by 3 months af-
ter treatment and left no
sequelae
“no ivermectin-treated
patients had uveitis at the
three year examination”.
(NOTE: placebo group
given ivermectin at 12
months)
39/291 (ivermectin) and
57/263 (placebo) RR 0.
62 (0.43 to 0.90)
Chorioretinitis Not reported “No new lesions were ob-
served in the fundus of the
eye.”
New or
progression of retinal pig-
ment epithelium atrophy
(an early manifestation
of chorioretinal change)
0/152 (ivermectin) 7/48
(placebo) RR 0.02 (0.00
to 0.32)
Chorioretinitis 28/
278 (ivermectin) 15/250
(placebo) RR 1.75 (0.91
to 3.37)
Optic nerve disease New
case of optic nerve disease:
45/1509 (ivermectin) 71/
1536 (placebo): RR 0.65
(0.45 to 0.93)
“No retinal or optic nerve
head changes were ob-
served on fluorescein an-
giography of the patients
who underwent this test”
“there were no new cases
of optic neuritis or op-
tic atrophy in any person
in any treatment group
throughout the study”
Op-
tic atrophy: 22/281 (iver-
mectin) 14/251 (placebo)
RR 1.40 (0.73 to 2.68)
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5. Adverse drug reactions
Adverse reactions included cutaneous reactions, musculoskeletal
reactions, fever, swelling of the face, joints and limbs, headaches
and dizziness, lymphadenopathy, eye reactions and nodule pain.
These reactions were either mild, moderate or severe.
Abiose 1993 and Taylor 1988 did not report adverse events.
In Dadzie 1989, 8/116 (6.9%) participants in the ivermectin
group compared with 0/38 (0%) in the placebo group reported
severe symptomatic postural hypotension (RR 9, 95% CI 0.55 to
147.9).
In Whitworth 1991a, 47/384 (12.2%) participants in the iver-
mectin group compared with 31/344 (9%) in the placebo group
reported adverse drug effects of any kind (RR 1.36, 95% CI 0.88
to 2.09).
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D I S C U S S I O N
Summary of main results
This review includes the results of two different types of studies:
two small studies in which people with onchocercal infection were
given one dose of ivermectin or placebo and followed up for one
year; and two larger community-based studies whereby all individ-
uals in selected communities were treated every six or 12 months
with ivermectin or placebo, whether or not they were infected,
and followed for two to three years.
As the two types of studies are addressing two different questions
we will consider them separately.
1. Ivermectin to prevent and treat onchocercal eye disease and
its consequences in people infected with O.volvulus
See ’Summary of findings for the main comparison’.
The results of Dadzie 1989 and Taylor 1988 provide evidence that
treating people who have onchocerciasis with ivermectin reduces
the number of microfilariae in their skin and eye (not shown in
the ’Summary of findings’ table) and reduces the number of punc-
tate opacities. There was weaker evidence that ivermectin reduced
the risk of chorioretinitis. There was no evidence for a protective
effect for sclerosing keratitis, iridocyclitis, optic nerve disease or
visual loss. However, the studies were too small and of too short a
duration to provide evidence on these less frequent consequences
of onchocercal infection.
2. Ivermectin to prevent and treat onchocercal eye disease in
people living in communities affected by O.volvulus
See ’Summary of findings 2’.
The results of one community-based study provides evidence that
annual mass treatment with ivermectin reduces the risk of new
cases of optic nerve disease and visual field loss in communities
mesoendemic for the savannah strain ofO.volvulus (Abiose 1993).
The other community-based study, with mass biannual treatment
of ivermectin in communities affected by the forest strain, demon-
strated reductions in microfilarial load (not shown in the ’Sum-
mary of findings’ table), punctate keratitis and iridocyclitis but not
sclerosing keratitis, chorioretinitis, optic atrophy or visual impair-
ment (Whitworth 1991a). However, this study was underpowered
to estimate the effect of ivermectin on visual impairment and other
less frequent clinical signs. Only a small number of new cases of
visual impairment developed over two years (11 cases in total, not
all of which could be attributed to onchocerciasis).
Adverse effects
In Whitworth 1991a, ivermectin was associated with a higher
prevalence of adverse drug reactions compared with placebo, how-
ever, this was not statistically significant. Dadzie 1989 showed a
nine-fold increased risk of severe symptomatic postural hypoten-
sion in the ivermectin group but this was not statistically signifi-
cant.
Overall completeness and applicability of
evidence
With only four trials included in this review, the evidence for iver-
mectin in the treatment of onchocercal disease is incomplete. We
can say with confidence that ivermectin reduces the microfilarial
load and number of punctate opacities. However, the evidence for
its effect on other signs of onchocercal eye disease, such as scleros-
ing keratitis, chorioretinitis and optic nerve disease is less certain.
Most importantly, the effect of ivermectin in preventing visual
loss, which is an outcome of primary importance to people suf-
fering from river blindness, is unclear. The trials included in this
systematic review were not primarily designed to evaluate the ef-
fectiveness of ivermectin in preventing onchocercal blindness and
this outcome was not commonly reported. The lack of evidence
for prevention of visual impairment and blindness should not be
interpreted to mean that ivermectin does not have these effects,
however, clearly this is a key question that remains unanswered.
Only two community-based trials are included in this review, one
conducted in communities mesoendemic for the savannah strain
in northern Nigeria and one in communities affected by the forest
strain in Sierra-Leone. The Nigerian study demonstrated a pro-
tective effect of mass treatment with ivermectin on the incidence
of optic nerve disease and visual field loss. However, it is unclear
whether this finding applies to other communities with higher or
lower infection rates and to communities affected by other strains
of O.volvulus. Several reports suggest that onchocercal blindness
is less common in forested areas compared with savannah areas,
where blindness rates can reach 15% (Burnham 1998; Pond 1991;
Stevenson 1999; WHO 1985). It is believed that the savannah
strain is more aggressive than the forest strain. These factors could
influence the overall response of participants to the treatment be-
ing evaluated.
The studies included in this review reported some adverse effects,
in particular an increased risk of postural hypotension in people
treated with ivermectin. Unlike diethylcarbamazine, ivermectin
does not rapidly eliminate microfilariae. This means that theMaz-
zotti reaction, which results from a massive overkill of numer-
ous macrofilariae all at once, is unlikely to be serious with iver-
mectin. However, none of the studies have been conducted in ar-
eas where people are infected with Loa loa (loiasis). Some studies
have suggested that serious neurological adverse effects can occur
when ivermectin is given to people with heavy infections of Loa
loa (Gardon 1997).
Quality of the evidence
All the trials included in this review used a placebo-controlled
group and therefore outcome assessment was graded as low risk of
bias. The use of a placeboprobablymeant that sequence generation
and allocation concealment were adequate as well but this was less
well reported. Information on follow-up was less well reported
18Ivermectin for onchocercal eye disease (river blindness) (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
and there may well be bias due to incomplete outcome data and
selective outcome reporting.
A limitation of this review is the fact that all four trials included are
published trials. It is possible that there are unpublished trials we
did not identify. If trials with negative findings are more likely to
remain unpublished (publication bias), the efficacy of ivermectin
may be overestimated in this review. Visual examination of a fun-
nel plot might have helped in determining the role of publication
bias in this review. Multiple trials, which have reported a common
outcome from which estimates of effects can be calculated, are
needed in order to carry out a funnel plot. None of the reported
outcomes in the four trials included in this review was uniformly
reported in all the trials. Furthermore, the primary outcome mea-
sure for this review was explicitly reported in only one trial. Exten-
sive efforts were made to contact pharmaceutical companies, trial
authors and acknowledged experts in the area of onchocerciasis
for unpublished trials of ivermectin for onchocerciasis in order to
reduce the risk of publication bias. None was identified.
Potential biases in the review process
The review methods were revised for the update in 2009. This
could have introduced bias if the choice ofmethodswas influenced
by knowledge of the results of the included trials. However, we
think this is unlikely as the methods used are fairly standard. The
conclusions of the review have not changed.
Agreements and disagreements with other
studies or reviews
The lack of convincing evidence for the effectiveness of ivermectin
in the prevention of onchocercal blindness was also noted by
Abiose in a narrative overview of onchocercal ocular disease and
the impact of ivermectin treatment (Abiose 1998). Abiose noted
that ’in none of the studies was there any evidence of a reduction
in the prevalence of blindness and a few new cases due to [on-
chocercal ocular disease] were observed. It may take a long time
for the effect of Mectizan on the incidence of blindness to become
apparent’.
Adverse effects have been noted in observational studies. In a re-
view of eight uncontrolled community trials to determine the
safety of ivermectin during large-scale treatment, De-Sole 1989
reported 49 cases of severe symptomatic postural hypotension
among 50,929 persons treated from eight countries. This repre-
sents an incidence of approximately 0.1% over 72 hours. Chijioke
1992 reported two cases of severe symptomatic postural hypoten-
sion among 7556 people treated with ivermectin in south-east
Nigeria. With the exception of rare serious reactions such as se-
vere systematic postural hypotension, ivermectin is generally well
tolerated (Goa 1991).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Some of the trials included in this review demonstrate that iver-
mectin may be effective in reducing punctate keratitis and iridocy-
clitis. However, its effectiveness in reducing chorioretinal lesions
and preventing visual acuity loss in onchocercal eye disease re-
mains unclear. The evidence for the effectiveness of ivermectin in
the reduction of the incidence of onchocercal visual field loss and
optic nerve disease reported in one trial with the savannah type
strain should be applied with caution to hyperendemic onchocer-
cal communities in which the forest type strain predominates.
As the benefits and harms of mass treatment with ivermectin are
not well established, treatment programmes should monitor the
effects of their programmes carefully.
Implications for research
The single most important public health problem posed by on-
chocerciasis is blindness and visual impairment. Future trials
should not only focus on the microfilaricidal properties of iver-
mectin, but also consider its effects on posterior segment lesions,
particularly chorioretinitis and its effectiveness in preventing vi-
sual acuity loss.
Given the widely held belief that ivermectin is the drug of choice
for preventing and controlling blindness due to onchocerciasis,
the present lack of suitable alternatives and ethical considerations
may make it difficult for placebo-controlled randomised trials of
ivermectin to be undertaken in the future. Scientists have intensi-
fied efforts on finding appropriate drugs which can kill the adult
worms of onchocerciasis. Recently some eight anti-cancer com-
pounds with potential macrofilaricidal properties have been iden-
tified (Kinnanom 2000). In addition, Dr Mark Taylor at the Liv-
erpool School of Tropical Medicine has reported potential macro-
filaricidal property of antibiotics of the tetracycline group. Certain
species of bacteria (Wolbachia) are known to infect filarial worms;
these probably play an important role in their fertility and con-
tribute to the pathogenesis of filarial disease. Tetracyline antibi-
otics ’cure’ the worms of their bacteria and in doing so affect the
viability of the worms (Hoerauf 2001; Taylor 2000). Current stud-
ies are underway which are investigating the effects of moxidectin
(NCT00790998) and doxycyline (ISRCTN95189962) relative to
ivermectin.
Future trials should have appropriate sample sizes allowing suffi-
cient power to detect important treatment differences with respect
to preventing visual loss in onchocerciasis. The duration of these
trials should be sufficiently long to be able to detect meaningful
changes in visual acuity. Anticipating that these trials would be in
rural communities, simple visual acuity tests such as the illiterate
E chart could be used and outcome measures could be reported
as ’proportion of participants in each treatment group becoming
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visually impaired or blind during follow-up’ using the WHO def-
inition. However, the visual acuity or visual field in the worse eye
rather than the better eye should define an individual with visual
impairment or blindness. This is to ensure that the real impact of
onchocerciasis on blindness and visual impairment is not under-
estimated.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abiose 1993
Methods Method of allocation: individual randomisation with a blocked design. Sequential ad-
ministration of pre-coded containers.
Masking: participants, provider and outcome assessors masked
Participants Country: Northern Nigeria.
Type of river blindness: savannah type.
Number randomised: 8136*.
Age: 5 years and above.
Sex: male and female.
Inclusion criteria: Individuals above 5 years normally resident in communities in which
the prevalence of positive skin snip for microfilariae among residents 20 years and over
was 30% or more.
Exclusion criteria: pregnant or lactating women; children < 5 years or weighing < 15 kg;
Individuals with disorders of the central nervous system or other debilitating disease.
Number of participants analysed for incidence of optic nerve disease after exclusion of
children < 15 years and individuals with optic nerve disease at baseline: 3045
Interventions Treatment: single dose ivermectin tablets taken orally and given annually for 3 years.
Dose: 150 ug/kg.
Control: placebo tablets taken orally and given once annually for 3 years.
Duration of follow-up: 17 to 39 months.
Outcomes Incidence of optic nerve disease, visual field deterioration
Notes Individuals who were 5 years or older were randomised but only individuals 15 years
and above were re-examined for outcome measures and included for analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation to the ivermectin or
placebo group was done at the individual
level with a blocked design.” Abiose 1993,
page 131, first paragraph.
Allocation concealment (selection bias) Low risk “At registration a master card was com-
pleted for each individual. It carried iden-
tification information, including a pho-
tograph, a unique pre-printed identifica-
tion number, and a pre-printed sequen-
tial treatment group number between 1
and 30. Merck, Sharp and Dohme donated
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Abiose 1993 (Continued)
30 identical containers, numbered 1-30, to
which ivermectin (6 mg per tablet) or a vi-
sually indistinguishable placebo tablet had
been randomly allocated. Each participant
received tablets from the container with the
same number as his or her card.
Staff conducting the trial were unaware
which containers held ivermectin.” Abiose
1993, page 131, first paragraph.
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “....3522 individuals examined at the first
examination were re-examined at least
once-an overall follow-up rate of 82%. The
mean duration of follow-up for these indi-
viduals was 2-54 (range 1.41-3.25) years.
There were no differences between the iver-
mectin and placebo groups in themean du-
ration of follow-up or in the proportions of
participants re-examined at each examina-
tion.” Abiose 1993, page 131, results, first
paragraph.
Communities endemic for onchocerciasis
were treated i.e. everyone aged 5 years
and above received ivermectin or placebo.
However, as very few people aged less than
15 years will experience significant on-
chocercal eye disease children under the age
of 15 years were not examined at follow-
up. Although this means that not everyone
treated was examined, as this was an a pri-
ori decision at study design stage, and in-
tervention/control groups were treated the
same it is unlikely to have lead to any bias
in estimating the effect of the intervention
Selective reporting (reporting bias) High risk No information on pre-specified outcomes
and only optic nerve disease and visual field
loss reported
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Dadzie 1989
Methods Method of allocation: individual randomisation with sequential administration of pre-
packed, precoded envelopes which were labelled with allocation numbers.
Masking:
Participants Country: Northern Ghana.
Type of river blindness: savannah type.
Area under concomitant vector control.
Number randomised: 198.
Age: 15 to 64 years.
Sex: male and female.
Inclusion criteria: not available.
Exclusion criteria: not available.
Interventions Treatment: single dose ivermectin tablets taken orally and given annually.
Dose: 100 ug/kg or 150 ug/kg or 200 ug/kg.
Control: placebo tablet given as single dose.
Duration of follow-up: 1 year.
Outcomes Systemic reactions to treatment; Visual function: improvement or deterioration; Skin
microfilariae load (geometric mean); Cornea, anterior chamber microfilarial load (geo-
metric mean)**; Punctate opacity load; Sclerosing keratitis; Iridocyclitis; Fundus changes
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk ”The doses of ivermectin or placebo were
formulated as identical capsules and pre-
sented in pre-packed, precoded envelopes,
each containing five capsules, and labelled
with weight ranges and allocation num-
bers. On admission into hospital, the pa-
tients were given the allocation numbers se-
quentially and the contents of the envelopes
with three weight ranges into which their
body weights fitted. This procedure gener-
ated four groups of patients: the first with
49 patients who took 100 mcg/kg; the sec-
ond with 50 patients who had 150 mcg/
kg, the third with 50 patients who received
200 mcg/kg body weight of ivermectin and
fourth with 49 patients who were given
placebo consisting of 185 mg corn starch
(STA-RX L500).“Dadzie 1989, page 356.
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Dadzie 1989 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk See above for allocation concealmentwhich
would also suggest that blinding was ade-
quate.However, ”The code of the studywas
broken after the month 6 review“ Dadzie
1989, page 356. The significance of this for
subsequent examinations (at 12 months) is
unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ”Only 154 of the 198 patients who were
ophthalmologically examined on all occa-
sions were considered in the analysis of the
results
Selective reporting (reporting bias) Unclear risk See Table 3
Taylor 1988
Methods Methodof allocation: Individual randomisationusing computer generated randomnum-
bers. Drug administered in coded packages.
Masking: provider, participants and outcome assessors masked
Participants Country: Grand Bassa County - Liberia.
Type of river blindness: forest type.
Number randomised: 200.
Age: 12 to 60 years.
Sex: male and female.
Inclusion criteria: heavy skin microfilarial count greater than 15 microfilariae/mg skin.
Exclusion criteria: pregnant and lactating women; people who had received anti-filarici-
dal drug within 1 year
Interventions Treatment: single dose ivermectin tablets taken orally and given annually.
Dose: 100 ug/kg or 150 ug/kg or 200 ug/kg.
Control: placebo tablet given as single dose.
Duration of follow-up: 1 year.
Outcomes Visual acuity; Visual field; Skin, cornea, anterior chamber microfilarial count (geometric
mean)**; Punctate opacity load (geometric mean)**; Ocular reaction index; Sclerosing
keratitis; Anterior uveitis; Retinal pigment epithelial atrophy; Optic nerve changes
Notes Number analysed in treatment groups not reported, therefore number randomised to
treatment groups used for analyses
Risk of bias
Bias Authors’ judgement Support for judgement
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Taylor 1988 (Continued)
Random sequence generation (selection
bias)
Low risk “Subjects were randomly assigned by us-
ing computer-generated random numbers
to receive 100, 150, or 200 µg/kg of iver-
mectin/kg or placebo” White et al 1987,
page 464, treatment protocol, first paragraph
Allocation concealment (selection bias) Low risk “The drug was provided in coded packages
containing five identical capsules; each pa-
tient was treated individually and closely
observed to ensure compliance.” Newland
1988, page 562, treatment protocol, first
paragraph
Also see below for “blinding”.
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Data were gathered in a double-masked
fashion and entered for computer analysis
prior to breaking the treatment code at six
months. The patients were examined at 12
months without reference to the treatment
code.” Newland 1988, page 562, treatment
protocol, first paragraph
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information on follow-up given.
Selective reporting (reporting bias) Unclear risk See Table 3
Whitworth 1991a
Methods Method of allocation: individual randomisation with a blocked design. Computer gen-
erated random numbers. Concealed allocation using coded containers.
Masking: provider, participants and outcome assessors masked
Participants Country: Southern Sierra-Leone.
Type of river blindness: forest type.
Number randomised: 1625.
Age: 1 year and above.
Sex: male and female.
Inclusion criteria: individuals normally resident in the study villages.
Exclusion criteria (after randomisation): children under five years; pregnant and one
month postpartum women; those with neurological disease including epilepsy; individ-
uals with severe intercurrent infection
Interventions Treatment: single dose ivermectin tablets taken orally and given 6 monthly.
Dose: 150 ug/kg body weight.
Control: placebo tablet given 6 monthly.
Duration of follow-up: 2 years.
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Whitworth 1991a (Continued)
Outcomes Incidence of blindness; Incidence of visual impairment; Skin microfilarial load (mf/mg)
(geometric mean)**; Prevalence of microfilariae in cornea, anterior chamber; Prevalence
of punctate keratitis, sclerosing keratitis, iritis, Chorioretinitis, retinal pigment epithelial
atrophy, adverse drug reactions
Notes Adverse reactions reported include: cutaneous reactions; musculoskeletal reactions; fever;
swellings of the face, joints or limbs; headache; dizziness; lymphadenopathy; eye reac-
tions; nodule pain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “All inhabitants of 6 study villages in south-
ern Sierra-Leone were allocated at random
to receive either ivermectin (150µg/kg) or
placebo throughout the trial.” Whitworth
et al Transactions of the Royal Society of Trop-
ical Medicine and Hygiene 1991, page 501
materials and methods.
Allocation concealment (selection bias) Unclear risk Control group received placebo but no in-
formation about allocation and how it was
concealed
Blinding (performance bias and detection
bias)
All outcomes
Low risk The control group received placebo and
even though there was no information
about allocation and how it was concealed
we have assumed that people were unaware
to which group they had been allocated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The eye study aimed to examine 312people
who had received four doses of placebo and
331 who had received four doses of iver-
mectin. 272 (87%) of the placebo cohort
and 296 (89%) of the ivermectin cohort
were examined. However original numbers
treatedweremuch higher ranging from812
to 870 in the ivermectin group and 813 to
875 in the placebo group
Selective reporting (reporting bias) Unclear risk Unclear see Table 3
* Number randomised to treatment or placebo not clearly specified. The value given is the number of individuals initially registered
and randomised.
** Standard deviation not reported therefore RevMan analysis for these outcome measures not possible.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Gardon 2002 All groups received ivermectin. No placebo group.
30Ivermectin for onchocercal eye disease (river blindness) (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Characteristics of included studies
Study Location Type of O.
volvulus in lo-
cality
Characteristics of participants Intervention
Total number
randomised
Mean age
(range)
% onchocercal
infection
Ivermectin Placebo
Abiose 1993* Nigeria savannah 4298 (15 to ?) 49% (age 5+)
72% (age 20+)
Approx 150
µg/kg
Four doses
over three
years
Four doses
over three
years
Dadzie 1989 Ghana savannah 198 32.5 (12 to 55) 100% 100, 150 and
200 µg/kg
One dose
185 mg corn
starch (STA-
RX L500)
One dose
Taylor 1988** Liberia forest 200 29.8 (12 to 60) 100% 100, 150 and
200 µg/kg
One dose
One dose
Whitworth
1991a
Sierra-Leone forest 643 people
who had re-
ceived 4 doses
ivermectin or
placebo
Es-
timated from
grouped data
at 41 years (5
to ?).
73% 150µg/kg at 0,
6,
12,18 months.
Everyone
received iver-
mectin at 24
months
0,6,
12,18 months.
All ivermectin
at 24 months.
*Everyone aged 5 years and above was treated with ivermectin or placebo, however, only people aged 15 years and above were examined
as part of the trial.
**800 people screened; of which 200 people with highest skin microfilarial counts were given ivermectin or placebo.
Table 2. Follow-up
Study Follow-up Ivermectin Placebo
Number ran-
domised
Number seen % seen Number
randomised
Number seen % seen
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Table 2. Follow-up (Continued)
Abiose 1993* Mean dura-
tion of follow-
up 2.54 years
(range 1.41 to
3.25)
? 1750 82 ? 1772 82
Dadzie
1989**
3, 6 and 12
months
149 116 77.9 49 38 77.9
Taylor 1988 3, 6 and 12
months
152 111 73.0 48 31 64.6
Whitworth
1991a***
24 months 331 296 89.4 312 272 87.2
*The trialists aimed to dose all trial participants aged 5 years or more with either ivermectin or placebo once a year for three years. 5021
individuals were registered in the trial and aged 15 years and older. Of these, 3522 (82%) were re-examined at least once during the
course of the trial. “There were no differences between the ivermectin and placebo groups in the mean duration of follow-up or in
the proportions of participants re-examined at each examination.”
** Data reported (number seen) for participants who had data for all three examinations.
*** From a larger study of 1745 people, 643 (331 ivermectin; 312 placebo) people who had received 4 doses of either ivermectin or
placebo were selected for the eye study.
Table 3. Outcome reporting grid
Outcome Type Abiose 1993 Dadzie 1989 Taylor 1988 Whitworth 1991a
Visual acuity Continuous E A E E
Visual acuity: %
with new visual im-
pairment (< 6/18)
Dichotomous E E
√ √
Visual acuity: %
with new blindness
(< 3/60)
Dichotomous
√
E
√
E
Visual field: % with
deterioration
Dichotomous
√
H
√
F
Microfilariae in skin Continuous E B C H (stated measured
pretreatment)
Microfilariae in skin Dichotomous / Cat-
egorical
E A E H (stated measured
pretreatment)
Microfilariae in
cornea
Continuous E B C E
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Table 3. Outcome reporting grid (Continued)
Microfilariae in
cornea
Dichotomous / Cat-
egorical
E E E
√
Microfilariae in an-
terior chamber
Continuous E B C E
Microfilariae in an-
terior chamber
Dichotomous /Cat-
egorical
E E E
√
Punctate keratitis %
new cases
Dichotomous E B D (geometric mean
punctate corneal opac-
ities reported)
√
Sclerosing keratitis
% new cases
Dichotomous E H E
√
Iridocyclitis % new
cases
Dichotomous E
√
E
√
Chorioretinitis %
new cases
Dichotomous E
√ √ √
Optic nerve disease
% new cases
Dichotomous
√ √ √ √
Adverse outcomes Dichotomous E
√
(postural hypoten-
sion)
B (Mazotti reaction)
√
Outcomes not prespecified in the review
Improvement in vi-
sual acuity 2+ lines
Dichotomous E A E E
Deterioration in vi-
sual acuity 2+ lines
Dichotomous E A E E
Glaucoma Dichotomous E E E Reported
Proportion visually
impaired or blind at
end of study
Dichotomous E E E Reported
Adapted from list provided by Paula Williamson at a Cochrane training workshop on selective outcome reporting bias, Edinburgh
March 2009.√
Data included in the review
A: States outcome analysed but only reported the P value > 0.05 i.e. NS
B: States outcome analysed but only reported that P value < 0.05
C: Clear that outcome was analysed but insufficient data presented to be included in meta-analysis or full tabulation
D: Clear that outcome was analysed but no results reported
33Ivermectin for onchocercal eye disease (river blindness) (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
E: Clear that outcome was measured (for example, includes structurally related outcomes) but not necessarily analysed
F: States that outcome was not measured
G: Not mentioned but clinical judgement says likely to have been measured
H: Not mentioned but clinical judgement says unlikely to have been measured
I: Other give details
Table 4. Effect of missing data
Outcome: visual field loss
Assumption regarding missing data Risk ratio 95% confidence interval
Missing at random (available case analysis) 0.60 0.41 to 0.89
Odds outcome in non-observed twice that
in observed in ivermectin and control
groups
0.61 0.42 to 0.90
Odds outcome in non-observed half that in
observed in ivermectin and control groups
0.60 0.40 to 0.89
Odds outcome in non-observed twice that
in observed in ivermectin and half in con-
trol groups
0.75 0.51 to 1.11
Odds outcome in non-observed twice that
in observed in ivermectin and half in con-
trol groups
0.49 0.33 to 0.72
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Onchocerciasis
#2 MeSH descriptor Onchocerca
#3 MeSH descriptor Microfilaria
#4 onchocerc* or oncocerc*
#5 river near blindness
#6 (#1 OR #2 OR #3 OR #4 OR #5)
#7 MeSH descriptor Ivermectin
#8 ivermectin*
#9 mectizan*
#10 ivomec*
#11 MeSH descriptor Albendazole
#12 albendazole*
#13 MeSH descriptor Levamisole
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#14 levamisole*
#15 (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14)
#16 (#6 AND #15)
Appendix 2. MEDLINE (OVID) search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp onchocerciasis/
14. exp onchocerca/
15. microfilaria/
16. (onchocerc$ or oncocerc$).tw.
17. (river adj2 blindness).tw.
18. or/13-17
19. ivermectin/
20. ivermectin$.tw.
21. mectizan$.tw.
22. ivomec$.tw.
23. albendazole/
24. albendazole$.tw.
25. levamisole/
26. levamisole$.tw.
27. or/19-26
28. 18 and 27
29. 12 and 28
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (Glanville 2006).
Appendix 3. EMBASE (OVID) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
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14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. onchocerciasis/
34. exp onchocerca/
35. exp microfilaria/
36. (onchocerc$ or oncocerc$).tw.
37. (river adj2 blindness).tw.
38. or/33-37
39. ivermectin/
40. ivermectin$.tw.
41. mectizan$.tw.
42. ivomec$.tw.
43. albendazole/
44. albendazole$.tw.
45. levamisole/
46. levamisole$.tw.
47. or/39-46
48. 38 and 47
49. 32 and 48
Appendix 4. metaRegister of Controlled Trials search strategy
onchocerciasis and ivermectin
Appendix 5. ClinicalTrials.gov search strategy
Onchocerciasis AND Ivermectin
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Appendix 6. ICTRP search strategy
onchocerciasis and ivermectin
WH A T ’ S N E W
Last assessed as up-to-date: 2 April 2012.
Date Event Description
16 July 2012 Review declared as stable This review will no longer be updated as current medical practice has evolved beyond
placebo comparisons. See ’Published notes’ for further information.
H I S T O R Y
Protocol first published: Issue 3, 2000
Review first published: Issue 1, 2001
Date Event Description
11 June 2012 New search has been performed Issue 8, 2012: Electronic searches were updated.
11 June 2012 New citation required but conclusions have not
changed
Issue 8, 2012: No new studies were identified that met
the inclusion criteria
12 August 2009 New search has been performed Issue 4, 2009: Updated searches yielded no new trials.
The background has been updated to include informa-
tion on Loa loa infection (loaisis). Four studies are in-
cluded instead of five as per the original published re-
view as one report was of a subset of patients included
in another trial
30 October 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
Conceiving the review: RW
Screening search results: HE, JE
Screening retrieved papers against inclusion criteria: HE, ES, JE
Appraising quality of papers: HE, ES, JE
Abstracting data from papers: HE,JE
Entering data into RevMan: HE, ES, JE
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Analysis of data: HE, RW,JE
Writing the review: HE, RW,JE
D E C L A R A T I O N S O F I N T E R E S T
Jennifer Evans worked on one of the included trials - Abiose 1993.
S O U R C E S O F S U P P O R T
Internal sources
• Institute of Ophthalmology, UK.
External sources
• British Council, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The main difference between the protocol and review is that we moved to assessing the risk of bias using The Cochrane Collaboration’s
tool for assessing risk of bias (Higgins 2011). In particular, we updated the methods for assessing the effect of heterogeneity, missing
data and selective outcome bias as well as the language used to describe the authors judgment for each ’Risk of bias’ domain.
N O T E S
After consulting with the Cochrane Eyes and Vision editorial base, the review authors have decided to no longer update this review.
The basis for this decision is in part due to ivermectin as the current standard of care which prohibits future placebo-controlled trials.
Additional advances in the treatment and elimination of onchocerciasis now include combination treatments with a single dose of
ivermectin plus daily doxycycline. Future Cochrane systematic reviews addressing additional therapies such as combination therapies
for the treatment and elimination of onchocerciasis will add to the current evidence summarised here.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anthelmintics [∗therapeutic use]; Ivermectin [∗therapeutic use]; Onchocerciasis, Ocular [∗drug therapy]; Randomized Controlled
Trials as Topic; Vision Disorders [parasitology; ∗prevention & control]
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MeSH check words
Humans
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